medigraphic.com
ISSN 1561-2988 (Print)

2022, Number 4

<< Back Next >>

Rev Cubana Farm 2022; 55 (4)

Genetic polymorphisms in a Colombian women population with breast cancer and tamoxifen consumption

Uribe EPT, Pérez AJM, Forero RMA, Betancur PJF

Language: English
References: 25
Page: 1-15
PDF size: 381.68 Kb.


ABSTRACT

Introduction: Breast cancer is positioned as the malignancy with the highest prevalence worldwide. In 2022, 2.2 million cases were reported. Colombia is considered the second country with the most frequent numbers of cancer in women. The epidemiological importance of this condition generates the need to establish in the region processes of demographic and clinical characterization, pharmacological intervention and identification of genetic variants, which determine a better understanding of cancer as a multifactorial situation.
Objective: To identify single nucleotide polymorphisms of CYP2D6*3, CYP2D*4 and ABCB1 C3435T in women with breast cancer with a history of tamoxifen consumption in the province of Caldas.
Methods: A descriptive and retrospective cross-sectional study was conducted in which 49 women from the department of Caldas, diagnosed with breast cancer on treatment with tamoxifen or aromatase inhibitors, who had a blood sample taken under the principles of bioethics and established biosafety criteria and protocols. Subsequently, DNA extraction was performed, followed by amplification of the CYP2D6 *3,*4 and ABCB1 (C3435T) alleles. The digestion of each of the alleles was completed with the restriction enzymes Mspl, MvaI and MboI, respectively.
Results: The CYP2D6*3 allele showed no polymorphisms in the analyzed population. The allele of the CYP2D6*4 gene presented polymorphism in the analyzed population: 78% were characterized as wild alleles (*1/*1) and 22% heterozygous alleles (*1/*4). 55.1% heterozygous alleles (TC) and 44.9% mutant homozygous alleles (TT) of the ABCB1 gene were found.
Conclusions: The alleles of the CYP2D6*4 gene were heterozygous in the population, finding association with intermediate or deficient metabolism, while not giving the adequate response to tamoxifen consumption, which led to the risk of breast cancer recurrence. The differences in the allelic frequencies of the ABCB1 gene suggest that half of the population analyzed presents the mutation and alteration in the membrane protein.


REFERENCES

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2020;71(3):209-49. Available in: https://pubmed.ncbi.nlm.nih.gov/33538338/

  2. World Health Organization. International Agency for Research on Cancer (IARC). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012 [cited 23/04/2016]. Available in: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

  3. Begam J, Jubie S, Nanjan M. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bio chem. 2017;71:257-74. DOI: 10.1016/j.bioorg.2017.02.011.

  4. Day S, Bevers TB, Goetz MP, Schaid DJ, Wickerham DL, Safgren S, et al. Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials. Clin Cancer Res. 2011;17:6944-51. DOI: 10.1158/1078-0432.CCR-11-0860.

  5. Pérez J, Betancur-Pérez J, Osorio-Solano C, Acosta M, Uribe P. Polimorfismos CYP2C19*2 y CYP2C19*3 en pacientes diagnosticadas con cáncer de mama. Revista Cubana de Farmacia. 2019 [cited 09/14/2021];52(1). Available in: http://www.revfarmacia.sld.cu/index.php/far/article/view/160

  6. Stipp M C, Acco A. Involvement of cytochrome P450 enzymes in inflammation and cancer: a review. Cancer Chemotherapy and Pharmacology. 2021,87(3):295-309. DOI: 10.1007/s00280-020-04181-2.

  7. Tornio A, Backman JT. Cytochrome P450 in pharmacogenetics: an update. Adv Pharmacol. 2018;83:3-32. DOI: 10.1016/bs.apha.2018.04.007.

  8. Madrid A, Cañadas M, Sánchez A, Expósito M, Calleja MA. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. Surg Oncol. 2017,26(4):473-82. DOI: 10.1016/j.suronc.2017.09.004.

  9. Balbuena HR. Papel del citocromo CYP2D6 en la era de la farmacogenética. Revista Cubana de Genética Comunitaria. 2011 [cited 04/16/2021];5(1):1-11. Available in: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=52244

  10. 10- Zanger U, Schwab M. Cytochrome p450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities and impact of genetic variation. Pharmacol Ter. 2013;38:103-41. DOI: 10.1016/j.pharmthera.2012.12.007.

  11. Batty J, Hall A, White H, Wikstrand J, De Boer R, Van Veldhuisen D, et al. An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients with Heart Failure: A MERIT-HF Substudy. Clin Pharmacol Ther. 2013; 95(3):321-30. DOI: 10.1038/clpt.2013.193.

  12. Quiñones L, Roco Á, Cayún JP, Escalante P, Miranda C, Varela N, et al. Clinical applications of pharmacogenomics. Rev. Med. Chil. 2017;145:483-500. DOI: 10.4067/S0034-98872017000400009.

  13. Sensorn I, Sukasem C, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, et al. ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. Onco Targets Ther. 2016;9(1):2121-29. DOI: 10.2147/OTT.S100905.

  14. Mandal A, Agrahari V, Khurana V, Pal D, Mitra AK. Transporter effects on cell permeability in drug delivery. Expert Opin Drug Deliv. 2017;14(3):385-401. DOI: 10.1080/17425247.2016.1214565.

  15. Tazzite A, Kassogue Y, Diakité B, Jouhadi H, Dehbi H, Benider A, et al. Association between ABCB1 C3435T polymorphism and breast cancer risk: a Moroccan case-control study and meta-analysis. BMC Genet. 2016, 17(1):126. DOI: 10.1186/s12863-016-0434-x.

  16. Hoffmeyer S, Burk O, Von Richter O, Arnorld HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and active in vivo. Proc Natl Acad Sci. 2000;97:3473-8. DOI: 10.1073/pnas.97.7.3473.

  17. Schur BC, Bjerke J, Nuwayhid N, Wong SH. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin Chim Acta Int J Clin Chem. 2001;08(1-2):25-31. DOI: 10.1016/S0009-8981(01)00422-3.

  18. Mathioudakis AG, Salakari M, Pylkkanen L, Saz‐Parkinson Z, Bramesfeld A, Deandrea S, et al. Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services. Psycho‐Oncology. 2019;28(5):939-47. DOI: 10.1002/pon.5041.

  19. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis primers. 2019;5(1):1-31. DOI:10.1038/s41572-019-0111-2.

  20. Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PloS One. 2013;8(12):e82562. DOI: 10.1371/journal.pone.0082562.

  21. Thota K, Prasad K, Rao M. Detection of cytochrome P450 polymorphisms in breast cancer patients may impact on tamoxifen therapy. Asian Pacific Journal of Cancer Prevention: APJCP. 2018 [cited 04/16/2020];19(2):343. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980918/

  22. Kevin Hicks, J., J Swen, J., & Gaedigk, A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.Current drug metabolism. 2014 [cited 04/16/2019];15(2): 218-32. Available from: https://www.ingentaconnect.com/content/ben/cdm/2014/00000015/00000002/art00007

  23. Gong L, Zhang CM, Lv J, Zhou H, Fan L. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenetics and genomics. 2017;27(9),337-46. DOI: 10.1097/FPC.0000000000000297.

  24. Goetz MP, Sangkuhl K, Guchelaar H-J, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin. Pharm. Therap. 2018;103(5):770-7. DOI: 10.1002/cpt.1007.

  25. Bezerra LS, Santos MAO, Bezerra NDS, Fonseca LCD, Sales WLA. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer. Impactos do polimorfismo genético do citocromo P450 2D6 (CYP2D6) na terapia com tamoxifeno para câncer de mama. Revista Brasileira de ginecologia e obstetricia. 2018;40:794-99. DOI: 10.1055/s-0038-1676303.




2020     |     www.medigraphic.com